Literature DB >> 6604055

Amino acid sequence of human beta-factor XIIa.

K Fujikawa, B A McMullen.   

Abstract

Human factor XII was activated by limited proteolysis with trypsin, and the resulting beta-factor XIIa (Mr = 30,000) was isolated by DEAE-Sephacel column chromatography. The complete amino acid sequence of beta-factor XIIa was then determined on peptides produced by enzymatic digestion with either trypsin, chymotrypsin, or Staphylococcus aureus V8 protease and by chemical cleavage at methionyl and tryptophyl bonds. beta-Factor XIIa is a glycoprotein composed of a heavy chain (243 amino acid residues) and a light chain (9 amino acid residues), and these two chains are held together by a disulfide bond. The carbohydrate is attached to asparagine residue 61 in the heavy chain. The amino acid sequence of the heavy chain shows a high degree of homology to the corresponding regions of other plasma serine proteases, such as plasmin, thrombin, factor IXa and factor Xa, as well as the pancreatic digestive enzymes. These results demonstrate that factor XII is the precursor of a typical serine protease that participates in the coagulation cascade.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6604055

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

1.  The search for a new model structure of beta-factor XIIa.

Authors:  E S Henriques; W B Floriano; N Reuter; A Melo; D Brown; J A Gomes; B Maigret; M A Nascimento; M J Ramos
Journal:  J Comput Aided Mol Des       Date:  2001-04       Impact factor: 3.686

2.  Specific types of activated Factor XII increase following thrombolytic therapy with tenecteplase.

Authors:  Volker Pönitz; David Pritchard; Heidi Grundt; Dennis Winston T Nilsen
Journal:  J Thromb Thrombolysis       Date:  2006-12       Impact factor: 2.300

Review 3.  Complement, Kinins, and Hereditary Angioedema: Mechanisms of Plasma Instability when C1 Inhibitor is Absent.

Authors:  Allen P Kaplan; Kusumam Joseph
Journal:  Clin Rev Allergy Immunol       Date:  2016-10       Impact factor: 8.667

4.  The heparin-catalysed inhibition of human factor XIa by antithrombin III is dependent on the heparin type.

Authors:  H Soons; G Tans; H C Hemker
Journal:  Biochem J       Date:  1988-12-15       Impact factor: 3.857

Review 5.  Factor XII: what does it contribute to our understanding of the physiology and pathophysiology of hemostasis & thrombosis.

Authors:  Evi Stavrou; Alvin H Schmaier
Journal:  Thromb Res       Date:  2010-03       Impact factor: 3.944

6.  Factor XII-induced mitogenesis is mediated via a distinct signal transduction pathway that activates a mitogen-activated protein kinase.

Authors:  E M Gordon; N Venkatesan; R Salazar; H Tang; K Schmeidler-Sapiro; S Buckley; D Warburton; F L Hall
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-05       Impact factor: 11.205

7.  Modulation of the human monocyte binding site for monomeric immunoglobulin G by activated Hageman factor.

Authors:  P Chien; R A Pixley; L G Stumpo; R W Colman; A D Schreiber
Journal:  J Clin Invest       Date:  1988-11       Impact factor: 14.808

8.  Coagulation factor XII (Hageman factor) Washington D.C.: inactive factor XIIa results from Cys-571----Ser substitution.

Authors:  T Miyata; S Kawabata; S Iwanaga; I Takahashi; B Alving; H Saito
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

9.  Mitogenic effects of coagulation factor XII and factor XIIa on HepG2 cells.

Authors:  K T Schmeidler-Sapiro; O D Ratnoff; E M Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-15       Impact factor: 11.205

10.  Induction of expression of monocyte interleukin 1 by Hageman factor (factor XII).

Authors:  Z Toossi; J R Sedor; M A Mettler; B Everson; T Young; O D Ratnoff
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.